Wilfried Posch

4.0k total citations
86 papers, 1.3k citations indexed

About

Wilfried Posch is a scholar working on Infectious Diseases, Immunology and Epidemiology. According to data from OpenAlex, Wilfried Posch has authored 86 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Infectious Diseases, 25 papers in Immunology and 22 papers in Epidemiology. Recurrent topics in Wilfried Posch's work include SARS-CoV-2 and COVID-19 Research (19 papers), Antifungal resistance and susceptibility (15 papers) and COVID-19 Clinical Research Studies (12 papers). Wilfried Posch is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (19 papers), Antifungal resistance and susceptibility (15 papers) and COVID-19 Clinical Research Studies (12 papers). Wilfried Posch collaborates with scholars based in Austria, Germany and France. Wilfried Posch's co-authors include Cornelia Lass‐Flörl, Doris Wilflingseder, Michael Blatzer, Viktoria Zaderer, Nina Lackner, Ulrike Binder, Dorothea Orth‐Höller, Günter Weiß, Martin Hermann and Manfred Nairz and has published in prestigious journals such as Nature Communications, Blood and PLoS ONE.

In The Last Decade

Wilfried Posch

79 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wilfried Posch Austria 22 575 313 296 296 173 86 1.3k
Maria Salomé Gomes Portugal 29 659 1.1× 402 1.3× 708 2.4× 350 1.2× 211 1.2× 61 2.0k
Doris Wilflingseder Austria 28 455 0.8× 390 1.2× 298 1.0× 665 2.2× 35 0.2× 92 1.8k
Birgid Neumeister Germany 22 531 0.9× 1.0k 3.2× 251 0.8× 459 1.6× 63 0.4× 53 2.1k
Thomas F. Byrd United States 22 1.1k 1.9× 411 1.3× 1.3k 4.3× 287 1.0× 86 0.5× 38 2.0k
Anuradha Chakraborti India 21 365 0.6× 529 1.7× 499 1.7× 251 0.8× 30 0.2× 98 1.7k
Paula M. Chilton United States 24 191 0.3× 522 1.7× 425 1.4× 1.3k 4.5× 61 0.4× 54 2.2k
Pongsri Tongtawe Thailand 22 221 0.4× 397 1.3× 206 0.7× 441 1.5× 47 0.3× 55 1.4k
Francisco J. Gómez United States 18 287 0.5× 286 0.9× 405 1.4× 260 0.9× 59 0.3× 46 1.1k
Manabu Yamada Japan 25 606 1.1× 235 0.8× 804 2.7× 114 0.4× 30 0.2× 123 2.0k
Anthony M. Smithyman United Kingdom 13 152 0.3× 290 0.9× 212 0.7× 321 1.1× 62 0.4× 28 1.5k

Countries citing papers authored by Wilfried Posch

Since Specialization
Citations

This map shows the geographic impact of Wilfried Posch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilfried Posch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilfried Posch more than expected).

Fields of papers citing papers by Wilfried Posch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilfried Posch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilfried Posch. The network helps show where Wilfried Posch may publish in the future.

Co-authorship network of co-authors of Wilfried Posch

This figure shows the co-authorship network connecting the top 25 collaborators of Wilfried Posch. A scholar is included among the top collaborators of Wilfried Posch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wilfried Posch. Wilfried Posch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zaderer, Viktoria, et al.. (2025). The Role of Enoxaparin in Influenza Virus Infections and its Therapeutic Implications. The Journal of Infectious Diseases. 233(1). e118–e131.
2.
Winter, Michael, et al.. (2025). Hypochlorous Acid (HOCl) as a Promising Respiratory Antiseptic. Viruses. 17(9). 1219–1219.
3.
Zaderer, Viktoria, Gabriel Diem, Wilfried Posch, et al.. (2024). P80 natural essence spray and lozenges provide respiratory protection against Influenza A, B, and SARS-CoV-2. Respiratory Research. 25(1). 102–102. 2 indexed citations
4.
Diem, Gabriel, Michael Jäger, Stefanie Dichtl, et al.. (2023). Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5. Microbiology Spectrum. 11(3). e0516322–e0516322. 1 indexed citations
5.
Jäger, Michael, Julia Kerschbaum, Michael Rudnicki, et al.. (2023). Virus-Subtype-Specific Cellular and Humoral Immune Response to a COVID-19 mRNA Vaccine in Chronic Kidney Disease Patients and Renal Transplant Recipients. Microorganisms. 11(7). 1756–1756. 1 indexed citations
6.
Bayerl, Felix, David Alejandro Bejarano, Anne‐Claire Doffin, et al.. (2023). Guidelines for visualization and analysis of DC in tissues using multiparameter fluorescence microscopy imaging methods. European Journal of Immunology. 53(11). e2249923–e2249923. 14 indexed citations
7.
8.
Zaderer, Viktoria, Gaia Lupoli, Christopher Dächert, et al.. (2023). Omicron subvariants illustrate reduced respiratory tissue penetration, cell damage and inflammatory responses in human airway epithelia. Frontiers in Immunology. 14. 1258268–1258268. 3 indexed citations
9.
Koblmüller, Stephan, et al.. (2022). The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitro. Virologica Sinica. 37(2). 198–207. 11 indexed citations
10.
Jäger, Michael, Stefanie Dichtl, Rosa Bellmann‐Weiler, et al.. (2022). Serum Neutralization Against SARS-CoV-2 Variants Is Heterogenic and Depends on Vaccination Regimen. The Journal of Infectious Diseases. 227(4). 528–532. 7 indexed citations
11.
Prelog, Martina, Giovanni Almanzar, Stephan Koblmüller, et al.. (2022). Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host. Nature Communications. 13(1). 2560–2560. 67 indexed citations
12.
Prelog, Martina, Chantal Rodgarkia‐Dara, Stephan Koblmüller, et al.. (2021). Maintenance of neutralizing antibodies over ten months in convalescent SARS‐CoV‐2 afflicted patients. Transboundary and Emerging Diseases. 69(3). 1596–1605. 9 indexed citations
13.
14.
Chatterjee, Sneha, Rafael Bayarri‐Olmos, Heribert Talasz, et al.. (2020). Shiga Toxin 2a Binds to Complement Components C3b and C5 and Upregulates Their Gene Expression in Human Cell Lines. Toxins. 13(1). 8–8. 2 indexed citations
15.
Posch, Wilfried, et al.. (2020). Role of Complement Receptors (CRs) on DCs in Anti-HIV-1 Immunity. Frontiers in Immunology. 11. 572114–572114. 2 indexed citations
16.
Hörtnagl, Paul, Thomas J. Hope, Arnaud Moris, et al.. (2019). Co- but not Sequential Infection of DCs Boosts Their HIV-Specific CTL-Stimulatory Capacity. Frontiers in Immunology. 10. 1123–1123. 1 indexed citations
17.
Brigotti, Maurizio, Dorothea Orth‐Höller, Domenica Carnicelli, et al.. (2018). The structure of the Shiga toxin 2a A‐subunit dictates the interactions of the toxin with blood components. Cellular Microbiology. 21(5). e13000–e13000. 23 indexed citations
18.
Váradi, Györgyi, László Galgóczy, Sándor Kocsubé́, et al.. (2018). The Evolutionary Conserved γ-Core Motif Influences the Anti-Candida Activity of the Penicillium chrysogenum Antifungal Protein PAF. Frontiers in Microbiology. 9. 1655–1655. 34 indexed citations
19.
Aßhoff, Malte, Verena Petzer, Matthew R. Warr, et al.. (2017). Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 129(13). 1823–1830. 156 indexed citations
20.
Posch, Wilfried, Kristian Pfaller, Cornelia Lass‐Flörl, & Doris Wilflingseder. (2014). The Viral Make-Up Makes a World of Difference. AIDS Research and Human Retroviruses. 30(7). 642–643. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Salomé Gomes Breakdown of academic impact, for papers by Doris Wilflingseder Breakdown of academic impact, for papers by Birgid Neumeister Breakdown of academic impact, for papers by Thomas F. Byrd Breakdown of academic impact, for papers by Anuradha Chakraborti Breakdown of academic impact, for papers by Paula M. Chilton Breakdown of academic impact, for papers by Pongsri Tongtawe Breakdown of academic impact, for papers by Francisco J. Gómez Breakdown of academic impact, for papers by Manabu Yamada Breakdown of academic impact, for papers by Anthony M. Smithyman
Rankless by CCL
2026